CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review reveals CPX-351 improves overall survival in acute myeloid leukemia, suggesting cost-effectiveness remains questionable.

Overall survival improved to 9.56 months with CPX-351 compared to 5.95 months with standard chemotherapy.
Key phase III trial reported a 47.7% complete remission rate, up from 33.3% with traditional treatment.
Analysis of real-world data highlighted notable remission rates, though prolonged cytopenias were common.
Finding raises concerns about generalizability and effectiveness in patients with TP53 mutations.

Konstantinidis et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark